Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Chapman

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Melanoma Research|December 1, 1992
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Y Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patientsG D Shah, N D Socci, J S Gold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancerP B Chapman, T J Lester, E S Casper, et al.
Cancer|September 15, 1991
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanomaT A Steffens, D F Bajorin, P B Chapman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanomaA A Jakubowski, D F Bajorin, M A Templeton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanomaP B Chapman, L H Einhorn, M L Meyers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Melanoma Research|December 1, 1992
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Y Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patientsG D Shah, N D Socci, J S Gold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancerP B Chapman, T J Lester, E S Casper, et al.
Cancer|September 15, 1991
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanomaT A Steffens, D F Bajorin, P B Chapman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanomaA A Jakubowski, D F Bajorin, M A Templeton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanomaP B Chapman, L H Einhorn, M L Meyers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Pageof 5